The clinical efficacy and outcomes of gefitinib therapy as a first-line treatment for elderly patients with nonsmall-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations were analyzed retrospectively. We analyzed chemotherapy-naïve NSCLC patients aged 75 years or older who had EGFR mutations (exon 19 deletion mutation or L858R), who were initially treated with gefitinib (250 mg) once daily in Nagano Prefecture. A total of 55 patients (16 men, 39 women) with a median age of 81.1 years (range; 75-94 years) treated between April 2007 and July 2012 were analyzed. The overall response rate and disease control rate were 72.7 % (95 % confidence interval (CI); 59.5-82.9 %) and 92.7 % (95 % CI; 82.0-97.6 %), respectively. Median progression-free survival and overall survival from the start of gefitinib treatment were 13.8 months (95 % CI; 9.9-18.8 months) and 29.1 months (95 % CI; 22.4 months-not reached), respectively. Two-year survival rate was 59.5 % (95 % CI; 41.0-78.0 %). Major grade 3 toxicities were skin rash (1.8 %) and increased levels of aspartate aminotransferase or alanine aminotransferase (7.3 %). First-line treatment with gefitinib for elderly EGFR-mutated NSCLC patients was effective and well tolerated. The results suggest that first-line gefitinib should be considered as a preferable standard treatment in elderly patients with advanced NSCLC harboring EGFR mutations.
Introduction
Lung cancer is the leading cause of cancer-related deaths in Japan and throughout the world [1, 2] . Non-small-cell lung cancer (NSCLC) accounts for 80-85 % of all lung cancers, and half of all patients already have metastatic disease with no indications for local therapy, such as surgery or radiotherapy, at the time of diagnosis. Furthermore, approximately 50 % of patients diagnosed with or dying from NSCLC are 70 years or older around the world [1] [2] [3] [4] . In general, doublet combinations of platinum compounds are standard regimens as first-line treatment in advancedstage NSCLC [5, 6] . However, only 13-17 % of patients over 70 years old were enrolled in previous studies [6, 7] . In addition, although it has been shown that the efficacy of chemotherapy for the elderly is similar to that in younger patients, it is generally more toxic in elderly patients in terms of both incidence and severity [5, 8] . Thus, based on several clinical studies [5, 8] , monotherapy with vinorelbine, gemcitabine, or docetaxel is recommended in advanced and non-selected NSCLC, especially in patients aged 75 years or older [9, 10] .
On the other hand, the current treatment paradigm focused on identifying potential predictors for treatment benefits, especially in molecular-targeted agents. Gefitinib, an oral small molecule agent that acts as an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the first molecular-targeted agent to be approved for the treatment of NSCLC patients. The extremely high response rate (RR) for gefitinib is associated with the presence of active EGFR mutations in tumor cells, such as in-frame deletions in exon 19 or point mutations in exon 21 (e.g., L858R) [11] [12] [13] . Several phase III trials comparing chemotherapy to gefitinib in a first-line setting demonstrated that gefitinib could produce improved progression-free survival (PFS) compared with platinum-containing chemotherapy in patients harboring EGFR-activating mutations [14] [15] [16] . However, these trials targeted NSCLC patients aged B75 years, and the clinical benefit of EGFR-TKI in EFGR-mutated NSCLC patients over 75 years old remains undetermined.
We previously conducted a prospective phase II study in elderly (C75 years old) EGFR-mutated patients with advanced NSCLC and reported RR of 58.6 % and median PFS of 12.9 months [17] . Subsequently, Maemondo et al. [18] reported RR of 74 % and PFS of 12.3 months in the same clinical setting. These results suggest that first-line gefitinib would be preferable to standard therapy in elderly patients. However, the numbers of patients enrolled in these studies were too small to elucidate the efficacy of first-line gefitinib. In the present study, we retrospectively evaluated the clinical outcomes in elderly patients (C75 years old) with advanced NSCLC and gefitinib-sensitive EGFR mutations in Nagano prefecture, Japan.
Patients and methods
We retrospectively analyzed patients aged 75 years or more treated in Shinshu University Hospital and associated hospitals in Nagano prefecture, Japan, from April 2007 to July 2012, who were EGFR-mutated NSCLC and received gefitinib as first-line therapy. The histological diagnosis and stage of NSCLC were based on the World Health Organization (WHO) classification version 3 [19, 20] and tumor-nodemetastasis (TNM) staging system [21] , respectively. Performance status (PS) was estimated according to the Eastern Cooperative Oncology Group (ECOG) classification.
Before therapy, each patient underwent physical examination, chest radiography, computed tomography scans of the thorax and abdomen, bone scintigraphy or F-18 fluorodeoxyglucose positron emission tomography, and magnetic resonance imaging scan of the brain to evaluate the TNM stage. If patients were diagnosed as having local NSCLC but were not suitable for thoracic surgery because of poor PS or other diseases, subjects treated with first-line gefitinib were included in the present analysis. We examined EGFR mutation status using the peptide nucleic acid-locked nucleic acid (PNA-LNA; Mitsubishi Chemical Medicine, Tokyo, Japan) PCR clamp method with paraffin sections of histological or cytological specimens. We defined gefitinib-sensitive EGFR mutations as exon 19 deletion mutation and L858R point mutation in the present study. For the identified and selected subjects, an electronic clinical record search was performed in each hospital, and patient privacy was protected when using individual information.
Gefitinib (250 mg) was administered orally once daily and continued until disease progression or intolerable toxicity. The response to gefitinib therapy was evaluated using the response evaluation criteria in solid tumors (RECIST) version 1.0 [22] . Disease control rate (DCR) was defined as the rate of complete response (CR) plus partial response (PR) plus stable disease (SD). Progression-free survival (PFS) was defined as the period from initiation of gefitinib therapy to the date of progressed disease (PD) confirmation or death from any cause. Overall survival (OS) was defined as the interval between the date of therapy initiation and the date of death from any cause or last follow-up. The survival curves were calculated using the Kaplan-Meier method. Toxicities associated with gefitinib therapy were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [23] . After failure of first-line gefitinib therapy, patients were permitted any subsequent treatments desired, including continuation of gefitinib treatment. Statistical analyses were performed using SPSS version 11.0 for Windows (IBM, Chicago, IL).
Results

Patient characteristics
Fifty-five patients harboring EGFR-mutated NSCLC were included in the analysis. The characteristics are listed in Table 1 . Thirty-nine were women (70.9 %), with a median age of 81.1 years (range 75-94 years). Thirty-nine patients were never smokers. The mean number of pack years in patients with smoking history was 22.7, ranging from 1.3 to 40. Forty-three patients (83.7 %) had PS of 0 or 1 according to ECOG, followed by 7 patients with PS 2 and 2 with PS 3-4. Histological type in all patients was adenocarcinoma. According to the TNM staging system, 3 patients had stage IIA disease, but they were considered to be medically inoperable because of poor PS and cerebrovascular disease. Two patients had stage IIIA disease, 4 patients had stage IIIB disease, and 40 patients had stage IV disease. There were 6 patients with postoperative recurrence. In terms of EGFR mutation, 31 patients had exon 19 deletion mutation and 24 patients had L858R point mutation. There were medical complications in the listed subjects. Four patients had concomitant malignant diseases, such as prostate and breast cancer, which were well controlled with hormonal therapy.
Response to gefitinib therapy and survival
The objective tumor response rate (RR) is described in Table 2 . One patient reached CR and 39 patients met the criteria of PR. Eleven patients showed SD during the observation period. Four patients showed PD. Thus, overall RR and DCR were 72.7 % (95 % confidence interval (CI); 59.5-82.9 %) and 92.7 % (95 % CI; 82.0-97.6 %), respectively. The median follow-up time was 16.0 months (range 1-48 months). The survival curves are shown in Fig. 1a , b. Median PFS was 13.8 months (95 % CI; 9.9-18.8 months; Fig. 1a) , and median survival time (MST) was 29.1 months (95 % CI; 22.4 months-not reached; Fig. 1b) . Two-year survival rate was 59.5 % (95 % CI; 41.0-78.0 %).
Toxicities
Toxicities were evaluated in all patients, and the main toxicities of first-line gefitinib therapy are summarized in Table 3 . The most common adverse event was skin toxicity. Skin rash was observed in 41.8 % of patients. Increased levels of AST or ALT appeared in 20.0 % of patients, and grade 3 or more was observed in 7.3 %. These serious adverse events were improved with temporary withdrawal of gefitinib or alternate-day administration. Alternate-day administration was performed in 13 patients (23.6 %). Other toxicities observed were mild. Interstitial lung disease (ILD) was observed in three subjects but improved with cessation of gefitinib therapy or corticosteroid therapy. Thus, none of the patients developed acute respiratory failure. ECOG eastern cooperative oncology group, EGFR epidermal growth factor receptor, Heart disease valvular disease, arrhythmia, ischemia, COPD chronic obstructive pulmonary disease a Subjects were current or former smokers 
Treatment after progression of disease
Information about second-line therapy after PD was unknown in 6 cases. Twenty patients were still receiving first-line gefitinib therapy without developing PD during the observation period. Table 4 lists the second-line therapy in the remaining 29 patients. Cytotoxic chemotherapy was performed in 7 patients. Three patients received carboplatin plus pemetrexed, and 4 patients received monochemotherapy with cytotoxic agents, including docetaxel, pemetrexed, or S-1. Eight patients continued EGFR-TKI by switching to erlotinib or continuing gefitinib. Thirteen patients received best supportive therapy without any second-line treatment. One patient received thoracic radiotherapy to the metastatic site.
Discussion
In the present study, we found that first-line gefitinib showed a high RR and extended survival time in elderly NSCLC patients harboring EGFR mutations. We reported in a previous prospective study that RR was 58.6 %, which was slightly less than in the present study (72.7 %) and another prospective study (74 %) [17] . The difference was due to the small number of patients enrolled in our previous trial (n = 17). The median PFS and 2-year survival rate in two previous prospective studies [17, 18] were reported to be 12.9, 12.3 months and 63, 61 %, respectively. The median PFS of 13.8 months and 2-year survival rate of 59.5 % obtained here were identical to the values in these previous prospective studies. In addition, several clinical phase III trials involving EGFR-mutated NSCLC patients demonstrated significantly longer PFS than in those receiving platinum-based combination chemotherapy [14] [15] [16] . These trials involved patients aged B75 years old, but the PFS ranged from 9.2 to 10.8 months. It is noteworthy that firstline gefitinib therapy in elderly EGFR-mutated NSCLC showed a prolonged PFS in comparison with younger patients. As the reason for this remains unclear, further clinical studies to determine the differences in efficacy of EGFR-TKI between age groups are warranted.
Toxicities with first-line gefitinib therapy in elderly patients were generally mild and predictable. The incidence and severity were also identical to those observed in patients aged B75 years old [14] [15] [16] . Three patients developed ILD, but responded well to corticosteroid treatment. No patients discontinued therapy due to gefitinib-related adverse events except ILD in this study.
A number of the patients in the present study suffered from other medical complications. Furthermore, the incidence of PS [2 was 16.4 % in the present analysis. These patients had a relatively low tolerance to standard first-line chemotherapy. As the introduction of first-line gefitinib in each case was dependent on the decision of the attending physician, our results may have included the clinical outcomes in elderly patients who were reluctant to receive first-line cytotoxic chemotherapy. For frail patients with EGFR-mutated NSCLC, for example, poor PS over grade 3 or elderly ([75 years old) with PS [ 2, it was demonstrated that first-line gefitinib therapy showed a high RR (66 %) and relatively long OS (17.8 months) [12] . Therefore, we believe that gefitinib is a good alternative as a first-line treatment for elderly patients.
At the time of data analysis, 7 of 29 relapsed subjects (24.1 %) received subsequent cytotoxic chemotherapy after failure of gefitinib therapy. Most patients (13/29; 44.8 %) eventually selected treatment with the best supportive care available. In the MILES study, which compared three chemotherapy regimen over 70 years old [24] , only 6-13 % of patients received second-line treatment with cytotoxic agent chemotherapy. In a Japanese study [10] , which compared docetaxel with vinorelbine in a population [70 years old, 47.5 % of patients received second-line chemotherapy; however, gefitinib was used as second-line chemotherapy in most cases (63.5 %). Thus, subsequent chemotherapy using cytotoxic agents in elderly patients with NSCLC was limited in elderly NSCLC patients in contrast to non-elderly patients. In addition, standard second-line treatments in elderly NSCLC have not been established. The influence of second-line or later therapies on overall survival in patients with EGFRmutated NSCLC remains unknown. We postulated that PFS extension may be evident in elderly patients, although the extension of PFS using gefitinib in non-elderly NSCLC was not reflected by achieving extension of OS. Thus, we suggest that elderly patients with sensitive EGFR mutations could be treated with first-line EGFR-TKI and should not miss out on the chance to receive EGFR-TKI therapy simply due to poorly timed administration. NEJ002, a phase III trial comparing gefitinib with carboplatin-paclitaxel as the first-line treatment for advanced NSCLC with sensitive EGFR mutations [14] , demonstrated that the quality of life (QOL) was maintained much longer in patients treated with gefitinib than in those treated with standard chemotherapy [25] . Unfortunately, we were unable to evaluate QOL in the present study. However, we speculated that the maintenance of QOL in elderly patients with EGFR-mutated NSCLC would be similar to that in patients less than 75 years old based on the results of prospective studies [13] . Thus, we recommend that firstline gefitinib therapy should be considered even focusing on the maintenance of QOL.
In conclusion, our results demonstrated remarkable efficacy and tolerance of first-line gefitinib in elderly EGFRmutated patients. Although this was a retrospective study, our results suggest that first-line gefitinib should be considered as a preferable standard treatment in elderly patients with advanced NSCLC harboring EGFR mutations. 
